Diverticulitis resident survival guide: Difference between revisions
Line 67: | Line 67: | ||
{{familytree | | | | B01 | | | | | | | | | | | | B02 | | | | | | | | | | B01= '''Uncomplicated''' | B02= '''Complicated'''<ref name="pmid16885694">{{cite journal| author=Floch MH| title=A hypothesis: is diverticulitis a type of inflammatory bowel disease? | journal=J Clin Gastroenterol | year= 2006 | volume= 40 Suppl 3 | issue= | pages= S121-5 | pmid=16885694 | doi=10.1097/01.mcg.0000225502.29498.ba | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16885694 }} </ref> }} | {{familytree | | | | B01 | | | | | | | | | | | | B02 | | | | | | | | | | B01= '''Uncomplicated''' | B02= '''Complicated'''<ref name="pmid16885694">{{cite journal| author=Floch MH| title=A hypothesis: is diverticulitis a type of inflammatory bowel disease? | journal=J Clin Gastroenterol | year= 2006 | volume= 40 Suppl 3 | issue= | pages= S121-5 | pmid=16885694 | doi=10.1097/01.mcg.0000225502.29498.ba | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16885694 }} </ref> }} | ||
{{familytree | | |,|-|^|-|.| | | | | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | |,|-|^|-|.| | | | | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | C01 | | C02 | | | | | | | | | | C03 | | | | | | | | | | C01= '''Outpatient''' <div style="float: left; text-align: left; padding:1em;"> | {{familytree | | C01 | | C02 | | | | | | | | | | C03 | | | | | | | | | | C01='''Outpatient''' <div style="float: left; text-align: left; padding:1em;"> | ||
❑ Inmunocompetent patient <br> ❑Tolerated oral intake<br> ❑Single episode<br> ❑Mild to moderate pain </div> | ❑ Inmunocompetent patient <br> ❑Tolerated oral intake<br> ❑Single episode<br> ❑Mild to moderate pain </div> | ||
| C02= '''Hospitalized''' <div style="float: left; text-align: left; padding:1em;"> ❑Unable to tolerate oral intake <br> ❑Severe pain <br> ❑Inmunocompromised patients </div> | | C02= '''Hospitalized''' <div style="float: left; text-align: left; padding:1em;"> ❑Unable to tolerate oral intake <br> ❑Severe pain <br> ❑Inmunocompromised patients </div> | ||
| C03= <div style="float: left; text-align: left; padding:1em;"> ❑[[Abscess]] <br> ❑[[Phlegmon]] <br> ❑[[Obstruction]] <br> ❑[[Fistula|Fistulization]] <br> ❑[[Bleeding]] <br> ❑[[Sepsis]] </div> }} | | C03= <div style="float: left; text-align: left; padding:1em;"> ❑[[Abscess]] <br> ❑[[Phlegmon]] <br> ❑[[Obstruction]] <br> ❑[[Fistula|Fistulization]] <br> ❑[[Bleeding]] <br> ❑[[Sepsis]] </div> }} | ||
{{familytree | | |!| | | |!| | | | | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | |!| | | |!| | | | | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | D01 | | D02 | | | | | | | | | | D03 | | | | | | | | | | D01= '''Medical Treatment'''<ref name="pmid18003962">{{cite journal| author=Jacobs DO| title=Clinical practice. Diverticulitis. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 20 | pages= 2057-66 | pmid=18003962 | doi=10.1056/NEJMcp073228 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18003962 }} </ref> <div style="float: left; text-align: left; padding:1em;"> ❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Quinolone]] | {{familytree | | D01 | | D02 | | | | | | | | | | D03 | | | | | | | | | | D01= '''Medical Treatment'''<ref name="pmid18003962">{{cite journal| author=Jacobs DO| title=Clinical practice. Diverticulitis. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 20 | pages= 2057-66 | pmid=18003962 | doi=10.1056/NEJMcp073228 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18003962 }} </ref> <div style="float: left; text-align: left; padding:1em;"> Oral regimens <br> | ||
❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Quinolone]] (e.g. [[Ciprofloxacin]] 500 - 700mg / 12hrs) <br> | |||
❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Trimethoprim]] (160mg / 12 hrs) - [[Sulfamethoxazole]] (800mg / 12hrs)<br> | ❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Trimethoprim]] (160mg / 12 hrs) - [[Sulfamethoxazole]] (800mg / 12hrs)<br> | ||
❑[[Amoxicillin]]- clavulanate (875mg / 12hrs) | ❑[[Amoxicillin]]- clavulanate (875mg / 12hrs) | ||
</div> | </div> | ||
| D02= | | D02= '''Medical Treatment'''<ref name="pmid18003962">{{cite journal| author=Jacobs DO| title=Clinical practice. Diverticulitis. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 20 | pages= 2057-66 | pmid=18003962 | doi=10.1056/NEJMcp073228 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18003962 }} </ref> <div style="float: left; text-align: left; padding:1em;"> Oral regimens <br>Intravenous regimen <br> | ||
| D03= | ❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Quinolone]] (e.g. [[Ciprofloxacin]] 400mg / 12hrs) <br> | ||
❑[[Metronidazole]] (500mg / 6 - 8 hrs) + [[Cephalosporin#Third generation|Third-generation cephalosporin]] (e.g. [[Ceftriaxone]] 1 - 2g / 12hrs) | |||
❑[[Beta-lactam]] with [[Beta-lactamase]] inhibitor (e.g. [[Ampicillin sulbactam]] 3g / 6hrs)</div> | |||
| D03= Stage the severity by using:<div style="float: left; text-align: left; padding:1em;"> | |||
❑ [[Diverticulitis resident survival guide#European Association for Endoscopic Surgery clinical Classification|European Association for Endoscopic Surgery clinical Classification]] <br> | |||
❑ [[Diverticulitis resident survival guide#Buckley Classification|Buckley Classification]] </div>}} | |||
{{familytree | | | | |,|-|^|-|.| | | |,|-|-|-|-|-|+|-|-|-|-|.| | | | | | }} | {{familytree | | | | |,|-|^|-|.| | | |,|-|-|-|-|-|+|-|-|-|-|.| | | | | | }} | ||
{{familytree | | | | E01 | | E02 | | E03 | | | | E04 | | | E05 | | | | | E01= | E02= | E03= | E04= | E05=}} | {{familytree | | | | E01 | | E02 | | E03 | | | | E04 | | | E05 | | | | | E01= | E02= | E03= | E04= | E05=}} | ||
Line 124: | Line 130: | ||
|} | |} | ||
====Buckley Classification==== | ====Buckley Classification<ref name="pmid18479497">{{cite journal| author=Sheth AA, Longo W, Floch MH| title=Diverticular disease and diverticulitis. | journal=Am J Gastroenterol | year= 2008 | volume= 103 | issue= 6 | pages= 1550-6 | pmid=18479497 | doi=10.1111/j.1572-0241.2008.01879.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18479497 }} </ref>==== | ||
{| Class="wikitable" | {| Class="wikitable" |
Revision as of 17:32, 21 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Andrea Tamayo Soto [2]
Definition
Causes
Life Threatening Causes
Common Causes
Management
Diagnostic Approach
Shown below is an algorithm depicting the diagnostic approach to diverticulitis according to the American Society of Colon and Rectal Surgeons[1] and the American Journal of Gastroenterology[2]
Characterize the symptoms:[3]
❑ Abdominal or preirectal fullness | |||||||
Obtain a detailed history:[4] ❑ Age
| |||||||
Examine the patient: ❑ Ectoscopy:
❑ Measure the heart rate
| |||||||
Order labs and tests:[3] | |||||||
Therapeutic Approach
Shown below is an algorithm depicting the therapeutic approach to diverticulitis according to the American Journal of Gastroenterology[2] and the American Society of Colon and Rectal Surgeons [1]
Initial Management | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Uncomplicated | Complicated[7] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outpatient
❑ Inmunocompetent patient ❑Tolerated oral intake ❑Single episode ❑Mild to moderate pain | Hospitalized ❑Unable to tolerate oral intake ❑Severe pain ❑Inmunocompromised patients | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Treatment[3] Oral regimens ❑Metronidazole (500mg / 6 - 8 hrs) + Quinolone (e.g. Ciprofloxacin 500 - 700mg / 12hrs) | Medical Treatment[3] Oral regimens Intravenous regimen ❑Metronidazole (500mg / 6 - 8 hrs) + Quinolone (e.g. Ciprofloxacin 400mg / 12hrs) | Stage the severity by using: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ I0}}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
European Association for Endoscopic Surgery clinical Classification[8]
Grades | Clinical Description |
Grade I
|
|
Grade II
|
Recurrence of above |
Grade III
|
|
Buckley Classification[2]
CT Findings | |
Mild |
Bowel wall thickening |
Moderate |
|
Severe |
|
Hinchey's Classification [3]
Stages | CT Findings |
Stage 1 |
|
Stage 2 |
|
Stage 3 |
|
Stage 4 |
|
Do´s
Don'ts
References
- ↑ 1.0 1.1 1.2 Feingold D, Steele SR, Lee S, Kaiser A, Boushey R, Buie WD; et al. (2014). "Practice parameters for the treatment of sigmoid diverticulitis". Dis Colon Rectum. 57 (3): 284–94. doi:10.1097/DCR.0000000000000075. PMID 24509449.
- ↑ 2.0 2.1 2.2 Sheth AA, Longo W, Floch MH (2008). "Diverticular disease and diverticulitis". Am J Gastroenterol. 103 (6): 1550–6. doi:10.1111/j.1572-0241.2008.01879.x. PMID 18479497.
- ↑ 3.0 3.1 3.2 3.3 3.4 Jacobs DO (2007). "Clinical practice. Diverticulitis". N Engl J Med. 357 (20): 2057–66. doi:10.1056/NEJMcp073228. PMID 18003962.
- ↑ Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H (2011). "How to diagnose acute left-sided colonic diverticulitis: proposal for a clinical scoring system". Ann Surg. 253 (5): 940–6. doi:10.1097/SLA.0b013e3182113614. PMID 21346548.
- ↑ Lamps LW, Knapple WL (2007). "Diverticular disease-associated segmental colitis". Clin Gastroenterol Hepatol. 5 (1): 27–31. doi:10.1016/j.cgh.2006.10.024. PMID 17234553.
- ↑ Tyau ES, Prystowsky JB, Joehl RJ, Nahrwold DL (1991). "Acute diverticulitis. A complicated problem in the immunocompromised patient". Arch Surg. 126 (7): 855–8, discussion 858-9. PMID 1854245.
- ↑ Floch MH (2006). "A hypothesis: is diverticulitis a type of inflammatory bowel disease?". J Clin Gastroenterol. 40 Suppl 3: S121–5. doi:10.1097/01.mcg.0000225502.29498.ba. PMID 16885694.
- ↑ Köhler L, Sauerland S, Neugebauer E (1999). "Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery". Surg Endosc. 13 (4): 430–6. PMID 10094765.